Friday, December 30, 2011

Pertuzumab improved PFS when given with trastuzumab, chemotherapy

SAN ANTONIO — According to data presented, patients with HER-2–positive metastatic or locally recurrent breast cancer had a longer PFS when they received a triple-drug combination that included pertuzumab, trastuzumab and docetaxel vs. patients who only received trastuzumab and docetaxel.

High-dose chemotherapy, autologous stem cell transplantation failed to improve OS in follicular lymphoma

Patients who underwent autologous stem cell transplantation for advanced follicular lymphoma did not experience an OS benefit, according to a systemic review and meta-analysis of trials involving 941 patients.